Abstract The generation of amyloid b-peptide (Ab) by enzymatic cleavages of the b-amyloid precursor protein (APP) has been at the center of Alzheimer's disease (AD) research. While the basic process of b-and c-secretasemediated generation of Ab is text book knowledge, new aspects of Ab and other cleavage products have emerged in recent years. Also our understanding of the enzymes involved in APP proteolysis has increased dramatically. All of these discoveries contribute to a more complete understanding of APP processing and the physiologic and pathologic roles of its secreted and intracellular protein products. Understanding APP processing is important for any therapeutic strategy aimed at reducing Ab levels in AD. In this review, we provide a concise description of the current state of understanding the enzymes involved in APP processing, the cleavage products generated by different processing patterns, and the potential functions of those cleavage products.
considered, offering additional strategies for an Ab-oriented therapy. However, over the recent years, more functions of the other APP cleavage products have emerged as well as more substrates of APP-cleaving enzymes. It must be recognized, therefore, that any intervention in APP processing is likely to affect more than just Ab production. In this review, we will have a look at the current state of knowledge of APP processing enzyme activities and the functions of various APP fragments. Interesting new findings have emerged recently, and it is, therefore, likely that more functions of APP fragments and APP processing enzymes will be discovered in the near future. sAPPa sAPPa is generated when a-secretase cleaves APP, a process also called shedding. The physiologic functions of sAPPa are poorly understood, but its actions have been generally considered beneficial to neurons. Early in vitro studies have demonstrated that sAPPa protects cultured neurons against oxygen-glucose deprivation and excitotoxicity by inhibiting calcium currents and increasing potassium currents and, thus, stabilizing the resting membrane potential (Mattson et al. 1993; Furukawa et al. 1996) . sAPPa also promotes neurite outgrowth, synaptogenesis, and cell adhesion (Mattson 1997; Gakhar-Koppole et al. 2008) . The biologically relevant site for these actions was located to the carboxy-terminus of sAPPa, spanning the region from just amino-terminal to the b-secretase cleavage site to the carboxy-terminal end with a heparin binding motif at the carboxy-terminus being of critical importance (Furukawa et al. 1996) . The amino-terminal end of sAPPa was not required for these effects. In vivo studies reported that sAPPa, when administered intracerebroventricularly, enhances learning and memory in mice and rats (Meziane et al. 1998; Taylor et al. 2008) . Interestingly, the latter study reported that this effect was accompanied by increased long-term potentiation (LTP) and enhanced N-methyl D-aspartate (NMDA) receptor-mediated currents, which is difficult to reconcile with the in vitro observations of increased potassium currents and reduced cytosolic calcium concentrations. However, Ishida et al. (1997) had reported that when applied to hippocampal slices recombinant sAPPa enhanced LTP and shifted the frequency dependence for induction of long-term depression (LTD), apparently by increasing cyclic GMP production. sAPPa also has been shown to act as a growth factor for cells of epidermal origin (Herzog et al. 2004; Siemes et al. 2006) to induce increased proliferation rates of embryonic and adult neural stem cells (Ohsawa et al. 1999; Caillé et al. 2004 ) as well as epidermal basal cells (Hoffmann et al. 2000 ) and increased migration rates in keratinocytes (Kirfel et al. 2002) . sAPPa is able to reverse most of the deficits seen in APP knockout mice (Ring et al. 2007 ). We conclude that sAPPa likely has growth promoting functions in dividing cells of epithelial origin, including embryonic and adult neural stem cells and plays a role in brain development. In differentiated neurons, sAPPa may have pro-survival functions, enhance neurite outgrowth, and improve memory formation, although the exact mechanisms for these actions are not yet fully understood.
While sAPPa concentrations in cerebrospinal fluid (CSF) are reduced in carriers of the Swedish APP mutation (APP 670/671) (Lannfelt et al. 1995) , in the cases of sporadic AD, they seem to be unaltered (Sennvik et al. 2000; Olsson et al. 2003) or increased (Lewczuk et al. 2008 Fig. 1 APP processing and cleavage products. The nonamyloidogenic APP processing pathway (right) involves cleavages by a-and c-secretases resulting in the generation of a long secreted form of APP (sAPPa) and C-terminal fragments (CTF 83, p3, and AICD50). The amyloidogenic APP processing pathway (left) involves cleavages by b-and c-secretases resulting in the generation of a long secreted form of APP (sAPPb), C-terminal fragments (CTF 99 and CTF 89) and Abs. Ab fragments oligomerize and fibrillize leading to AD pathology (left and upper panel). ex extracellular, PM plasma membrane, cyt cytosol, DR6 death receptor 6 in the case of the Flemish mutations also AD-like dementia and neuropathology. In these cases, both the altered Ab sequence and reduced a-secretase cleavage of APP may contribute to the clinical picture.
a-Secretase a-Secretase activity is generally attributed to the ADAM family of proteases. Among this family, ADAM 9, 10, 17, and 19 have been shown to exert a-secretase activity (Fahrenholz et al. 2000; Asai et al. 2003; Tanabe et al. 2006) . At the moment, it is unclear which of these is the relevant protease in AD patients. However, in a mouse model of AD, Adam 10-overexpression has been shown to reduce Ab production and plaque deposition in addition to lessening cognitive deficits (Postina et al. 2004) . Therefore, ADAM 10, at the moment, is a good candidate to be a relevant a-secretase in AD pathogenesis. However, given the existing redundancy of ADAMs, it is quite possible that more than one ADAM is involved in sAPPa generation. a-secretase activity has a constitutive and an inducible component that depends on its subcellular localization. a-secretase at the plasma membrane surface is considered constitutively active, and it is believed to be the main proteolytic pathway for APP that reaches the plasma membrane (de Strooper and Annaert 2000) . On the contrary, a-secretase that resides in the trans-Golgi network is regulated by PKC and competes with b-secretase in the same location (Skovronsky et al. 2000) . It is not clear which specific ADAM protein is associated with constitutive and inducible a-secretase activity, but ADAM 10 can be activated by calcium (Le Gall et al. 2009 ). Neuronal depolarization will lead to PKC activation and increased vesicle and membrane turnover, and accordingly, neuronal activity was shown to increase a-secretase activity in an NMDA receptor-dependent and calcium-sensitive fashion in mature neurons and neuron precursor cells (GakharKoppole et al. 2008; Hoey et al. 2009 ). However, the opposite (i.e., reduced a-secretase activity) upon neuronal depolarization has been reported as well (Lesné et al. 2005) . APP is only one of many substrates for ADAM family proteins; others include N-cadherin (Kohutek et al. 2009 ), EGFR ligands, TNF-a, TGF-a, notch, and ephrin (Edwards et al. 2008; Le Gall et al. 2009 ). While a dominant negative mutant of ADAM 10 caused increased sensitivity to kainate-induced epileptic seizures in mice overexpressing the APP V717I (London) mutation, it reduced sensitivity to seizures in wild type mice. Similarly, surprising results were obtained with overexpression of wild type ADAM 10, which was associated with an increased rate of seizures in both wild-type and APP V717I mice (Clement et al. 2008) . One possible interpretation is that in a context of increased Ab production, reducing sAPPa (and possibly further increasing Ab) is the dominant biologic effect of dominant negative a-secretase, whereas other effects of a-secretase (i.e., cleavage of proteins other than APP) become dominant, when the dominant negative mutant is expressed in a wild-type context, or when a-secretase is overexpressed. If this interpretation is correct, then it has to be assumed that one or more of a-secretase's cleavage products have the potential to facilitate seizures, but Ab has a greater potential to do so.
P3
No clear biologic role has been established for the P3 fragment that is generated by a-and c-secretase cleavage of APP. sAPPb sAPPb is the secreted amino-terminal fragment that is generated when b-secretase cleaves APP. sAPPb lacks most of the neuroprotective effects that have been associated with sAPPa (Furukawa et al. 1996) . A recent report demonstrated that sAPPb is critically involved in pruning of synapses during development of both central and peripheral neurons (Nikolaev et al. 2009 ). In this study, sAPPb was found to act as a ligand for the death receptor 6 (DR6) (a member of the TNFa family), which, upon binding, leads to cleavage and activation of caspase 6, but not caspase 3. This caspase 6 activation was associated with disintegration of axons, but not cell somata. Importantly, sAPPb generation was induced by trophic factor withdrawal, and sAPPb could also bind to p75 neurotrophin receptor (p75NTR), albeit with lower sensitivity and no clear biologic relevance in the context that was studied. Other functions of sAPPb may include suppression of neuronal stem cell differentiation in favor of glial differentiation (Kwak et al. 2006 ), but these actions are not well characterized.
b-Secretase
b-Secretase activity is mediated by BACE1 and cleaves APP to release sAPPb and produce CTF99. BACE1 can also cleave APP at a more carboxy-terminal position, resulting in CTF89 (and Ab 11-40 after c-secretase cleavage) (Fig. 2) . A related protein, BACE2, also can exert b-secretase activity (Hussain et al. 2000) , but it is expressed at very low levels in the brain and is mostly confined to glial cells (Laird et al. 2005) ; interestingly, BACE2 is a better a-than b-secretase (Farzan et al., 2000) . BACE2 appears irrelevant to AD pathogenesis and will not be considered in this review. Genetic ablation of BACE1 completely prevents the amyloid pathology in a mouse model expressing the Swedish mutation of APP (APP670/ 671), together with mutated PS1 (Farzan et al. 2000; Laird et al. 2005) , or in mice expressing only the Swedish APP mutation (Tg2576) (Ohno et al. 2004 ). BACE1-deficient mice lack b-secretase activity and Ab formation in neurons (Cai et al. 2001; Roberds et al. 2001; Luo et al. 2001 . Also, BACE1 expression and activity are increased in brains of AD patients (Holsinger et al. 2002; Yang et al. 2003) .These studies provide the rationale for the current view that BACE1 is the physiologically relevant b-secretase in the brain that contributes to AD pathology. At the end of this section, however, we will also have a look at cathepsins as enzymes with potential b-secretase activity.
BACE1 expression is increased in situations of cellular stress, e.g., energy deprivation, hypoxia, and ischemia (O'Connor et al. 2008; Guglielmotto et al. 2009 ), and oxidative stress has been shown to increase BACE1 expression in a c-secretase dependent fashion (Jo et al. 2008) . BACE1 is synthesized as a proenzyme in the endoplasmic reticulum (that nonetheless possesses b-secretase activity). Homodimerization, cleavage of the prodomain in the transGolgi network by furin or furin-like proteases and complex glycosylation are further steps toward the fully active enzyme (Westmeyer et al. 2004; Cole and Vassar 2008; Hunt and Turner 2009) . BACE1 can be further cleaved to be released from the plasma membrane (shedding). Shedding of BACE1 likely depends on proteases of the ADAM family which appears to be an interesting connection between a-secretase and BACE1. The function and relevance of BACE1 shedding remain unclear at the moment. Other posttranslational modifications occur and have an impact on BACE1 activity (see Hunt and Turner 2009 for review) . The subcellular localization of BACE1 is predominantly within the trans-Golgi network and endosomal compartment (Huse et al. 2002) . Although BACE1 reaches the plasma membrane due to vesicle traffic, it is recycled quickly, and very little BACE1-mediated APP cleavage occurs at the plasma membrane; instead, APP is cleaved by BACE primarily in endocytic vesicles. Interestingly, within the secretory pathways of the endoplasmic reticulum and trans-Golgi network, APP and BACE1 are located in separate membrane microdomains, due to APP binding to X11/Munc18 proteins (Saito 2008) . Neuronal depolarization leads to Munc18 phosphorylation and causes APP to relocalize in BACE1-containing membrane microdomains (Sakurai 2008) . Accordingly, neuronal depolarization and vesicle turnover have been shown to increase BACE1-mediated APP cleavage and Ab production (Kamenetz et al. 2003) . Thus, increased neuronal depolarization increases APP cleavage by both a-secretase and BACE1 in a competitive fashion (Kamenetz et al. 2003 ). It will, therefore, be of interest to determine whether neuronal activity can be fine-tuned to increase one activity over the other (Hoey et al. 2009 ). BACE1 is located in cholesterolrich lipid rafts (Abad-Rodriguez et al. 2004 ), but whether lowering brain cholesterol levels in AD patients will actually reduce Ab generation and improve cognitive function remains to be seen (Abad-Rodriguez et al. 2004; Cheng et al. 2007; Vetrivel et al. 2009 ).
BACE1 has many other substrates apart from APP. They include APP-like proteins 1 and 2 (APLP1 and 2), voltagegated sodium channel b2-subunit, low density lipoprotein receptor-related protein, neuregulin 1, P-selectin glycoprotein ligand-1, and sialyltransferase ST6Gal I (Hunt and Turner 2009) . BACE1 knockout (BACE1 -/-) mice show some interesting phenotypes. They show a rather severe hypomyelination of peripheral nerves (Willem et al. 2006 ), but only modest hypomyelination in the CNS (Hu et al. 2006) . They also have an increased rate of seizures, which is even higher when BACE1 -/-mice are crossed with PDAPP mice (Kobayashi et al. 2008) . BACE1 genetic ablation also causes a reduction in spine density in hippocampal pyramidal neurons and alterations in behavior tests that are believed to reveal schizophrenia-like phenotypes, including reduced pre-pulse inhibition, noveltyinduced hyperactivity, hypersensitivity to the NMDA receptor antagonist MK-801, as well as impairments in cognition and social recognition (Savonenko et al. 2008) . It is possible that these effects are mediated through impaired processing of non-APP substrates, with neuregulin 1 being a very likely candidate. It is interesting to note, however, that the (modest) deficit that BACE1 -/-mice display in the Morris water-maze test was not seen when BACE1 were crossed with APPswe/PS1DE9 transgenic mice, while the deficits in social recognition remained unaltered (Laird et al. 2005) . These leaves open the possibility that increased APP expression and/or processing through a-and c-secretase can compensate for some of the deficits of BACE1 deficiency. The view that BACE1 is the only relevant b-secretase in AD has been challenged recently as other proteases, specifically cathepsins, have been shown to exert b-secretase activity (Hook et al. 2005 (Hook et al. , 2007a (Hook et al. , b, 2008 Schechter and Ziv 2008; Böhme et al. 2008; Klein et al. 2009 ). A possible explanation for these findings and the seemingly discrepant results of Cai et al. (2001) , Roberds et al. (2001) , and Luo et al. (2001) is that cathepsins cleave wildtype (wt) human APP but not human APP that is mutated at the b-secretase cleavage site (mtAPP) as is the case in transgenic AD models that use an APP form containing the Swedish mutation (K670 N/M671L). Accordingly, genetic ablation of cathepsin B has been reported to reduce Ab 1-40 and Ab 1-42 levels in the brains of mice that overexpress human wtAPP but not mtAPP with the Swedish and Indiana (V717F at the c-secretase cleavage site) mutation (Hook et al. 2009 ). The finding that the overexpression of BACE1 does not result in increased levels of endogenous (murine) Ab may point to a similar direction (Hirata-Fukae et al. 2008) . Also, the conversion of the aspartate residue at the b-secretase cleavage site to isoaspartate by a nonenzymatic reaction has been reported to be a frequent event resulting in loss of BACE1 but not cathepsin B activity at the b-secretase site (Böhme et al. 2008 ). However, the picture becomes more complex if it is considered that cathepsin B can also degrade Ab 1-42 and genetic ablation of cathepsin B has been reported to lead to increased plaque load and Ab 1-42 levels in mice with the Swedish and Indiana mutation of APP (Mueller-Steiner et al. 2006) . Accordingly, genetic ablation of the cathepsin B inhibitor cystatin C leads to reduced plaque load and Ab 1-42 levels in the same mice (Sun et al. 2008) . Thus, the role of cathepsin B in AD needs to be further investigated as it may contribute to both Ab generation and degradation. The seemingly conflicting results of some of these studies are a reminder that mouse models only imperfectly replicate the human disease, and it is important to realize that unlike all mouse models, the majority of sporadic AD cases neither contain mutations in the APP nor Presenilin genes. It is, therefore, important to further investigate potential differences in wtAPP versus mtAPP processing.
Ab
Ab is at the center of AD pathogenesis. It is generated through sequential cleavage of APP by b-and c-secretases.
The resulting peptide is predominantly 40 amino acids long but peptide length can range from 38 to 43 amino acids. Certain forms (e.g., Ab 1-42, 3-40) are considered more amyloidogenic than others (e.g., Ab1-40 or 1-38). Since both BACE1 and c-secretase activity are located in the endosomal compartment and trans-Golgi network, it is believed that most Ab is generated in these subcellular localizations and subsequently secreted through exocytosis. Intracellular Ab has been observed as well, both in animal models of AD and human patients (Wirths et al. 2001; Gómez-Ramos and Asunción Morán 2007) , the significance of which remains rather uncertain (Wegiel et al. 2007 ). Ab can be cleaved by proteases such as insulin degrading enzyme (Kurochkin and Goto 1994) , neprilysin (Iwata et al. 2000) , BACE1 (Huse et al. 2002) and cathepsin B (only Ab 1-42) (Mueller-Steiner et al. 2006) . While insulin degrading enzyme, neprilysin, and cathepsin B render Ab non-amyloidogenic, the significance of Ab 11-40, which is generated by BACE1 cleavage of Ab at the b' site, has not yet been established. Other modifications include pyroglutamate formation of the amino-terminal glutamic acid residue through glutaminyl cyclase resulting in amino-terminal truncated pyroglutmate Ab 3-40/42, which is highly amyloidogenic; inhibition of glutaminyl cyclase improves amyloidosis and cognition in mouse models of AD (Schilling et al. 2008) . Conversion of aspartate to isoaspartate at residue 23 in the Ab sequence also has been reported to increase Ab aggregation (Shimizu et al. 2002) . Ab production is either increased or the ratio of Ab42-40 is increased in most hereditary cases and animal models of AD. In AD patients, Ab levels in the CSF are not increased, rather Ab42 reduction in CSF is a good biomarker for AD (Shaw et al. 2009 ). This reduction in Ab42 likely reflects reduced clearance of Ab through the CSF and increased accumulation in amyloid plaques.
The currently predominant hypothesis states that Ab forms soluble oligomers in the extracellular space and that these oligomers inhibit NMDA-mediated synaptic transmission and ultimately cause spine and synapse loss through mechanisms not yet fully understood (Selkoe 2000) . In a study using extracts from brains of AD patients and hippocampal slice cultures, Ab dimers were shown to be the most potent form of Ab oligomers to inhibit NMDAmediated synaptic transmission, and higher molecular weight oligomers and insoluble aggregates were able to release Ab dimers (Shankar et al. 2008) . Most studies of Ab toxicity have been performed with synthetic peptides of various lengths (e.g., 1-40, 1-42, and 25-35). In general, caution must be exercised when translating such results to in vivo situations as oligomerization status and post translational modifications of endogenous Ab are different than synthetic peptides. Notably, concentrations required to elicit Ab toxicity in vitro with synthetic peptides are in the 5-10 lM range, which is higher than Ab concentrations likely encountered by neurons in vivo. Also, in human primary neuron cultures 10 lM Ab 1-38 and 25-35 are alone not toxic, but a preincubation for 3 days leads to increased sensitivity to glutamate toxicity (Mattson et al., 1992) . One interesting interaction that has been reported recently is between Ab and cellular prion protein (PrP) (Laurén et al. 2009 ). In this study, Ab oligomers of *100 molecules would exert their inhibitory effect on NMDAmediated synaptic transmission only when they could bind to the cellular form of PrP. In PrP deficient mice, this interaction was absent, and Ab peptides were not inhibitory or toxic. Other interactions between APP or Ab and PrP, and reciprocal modulation of AD or scrapie disease progression in mouse have been described as well (Baier et al. 2008 , Tamgüney et al. 2008 ); moreover, cellular PrP was shown to inhibit BACE1-mediated Ab production (Parkin et al. 2007 ).
CTF83 and CTF99
No biologically relevant roles are currently established for the carboxy-terminal fragments CTF83 and CTF99 generated by a-and b-secretase, respectively. A more carboxyterminal cleavage of APP by b-secretase cleavage results in a CTF89, the function of which also is unclear.
AICD
AICD is generated when c-secretase cleaves CTF83 or CTF99. Although c-secretase cleavage of APP to release Ab results in an AICD fragment of 57 or 59 amino acids, another cleavage site (e-cleavage site), just a few amino acids toward the carboxy-terminal end, will result in a 50-amino acid AICD fragment (Fig. 2) . This is mostly considered the typical AICD, but more cleavage sites for c-secretase and also for caspase 3 have been reported, resulting in even shorter peptides (e.g., AICD 31 after caspase 3 cleavage). Regardless of the cleavage site, AICD of various lengths still contains the consensus motif YE-NPTY that is thought to be crucial for AICD binding to adapter proteins such as Fe65 and subsequent biologic actions. The term AICD has been coined by analogy to protease cleavage of the protein Notch, another c-secretase substrate, which results in release of the Notch intracellular domain (NICD). c-secretase-mediated cleavage of Notch is a critical step in the Notch signaling cascade, and this similarity has fostered much research into AICD. The AICD peptide can undergo more posttranslational modifications, including phosphorylation (see Müller et al. 2008 for review). The prototypical signaling pathway for AICD includes binding to the protein Fe65, then recruitment of the histone deaceytelase TIP60, nuclear translocation and transcriptional activation of target genes such as p53, GSK3b, neprilysin, EGFR, and others. Apart from this pathway many other AICD binding proteins and effects have been described. However, these pathways have been studied mainly in cell lines, sometimes in primary neurons, but hardly in vivo in the brain, making any extrapolation of existing results into the context of AD brains very speculative. Moreover, not all research groups can confirm even the prototypical pathway of AICD binding to Fe65 and nuclear translocation with target gene transcription (Waldron et al. 2008) , leaving a fair amount of controversy in the debate. Transgenic mice that overexpressed both AICD and Fe65 have abnormal EEG recordings and increased susceptibility for seizures, features also seen in mice overexpressing APP with the Swedish mutation but not in mice with the Swedish and Indiana mutation as well as a disruption of the caspase cleavage site in the AICD sequence (D664A) ). Overexpressing AICD with Fe65 also leads to hyperphosphorylation of the microtubule associated protein tau and to neuronal cell loss in animals 18 months and older (Ghosal et al. 2009 ). Importantly transgenic mice overexpressing only Fe65 did not show any of these features. However, since no data are available on the effect of AICD overexpression only we feel that, as of now, the role of AICD in AD pathogenesis remains to be firmly established, and future experiments using human APP constructs with mutations in the e-cleavage site or the YENPTY domain should provide a clearer picture. In an elegant approach, wtAPP lacking the YENPTY domain was reintroduced into APP knockout mice (Ring et al. 2007) . As a result, Ab generation was quite drastically reduced compared with wild-type mice, probably due to the increased cell surface expression of APP and reduced entry into the endocytic pathway, pointing to a role for AICD in APP trafficking. The results indicate that a clear-cut separate role for AICD may be difficult to establish as the domain may serve multiple roles in full-length APP and after cleavage. This consideration applies, of course, not just to AICD but to other products of APP cleavage as well.
c-Secretase
c-secretase cleaves APP in its intra-membrane region at the c-cleavage site to generate Ab 1-40/42 or p3 and AICD59/ 57, a second cleavage at the e-cleavage site results in AICD50 (Fig. 2) . At least four proteins need to interact for c-secretase activity to unfold: PS1 or 2, Nct, Aph-1, and Pen2 (Wolfe 2008) . Aph-1 exists in two isoforms, Aph-1a and b, encoded by two genes in humans; mice have a third isoform, Aph-1c. PS1 and 2 have the actual protease activity, and in the brain, PS1 is the dominant presenilin. The full-length PS proteins contain nine transmembrane regions and are cleaved in the cytoplasmic loop between the 6th and 7th transmembrane region to generate an amino-terminal and carboxy-terminal fragments (Thinakaran et al. 1996) . Both fragments are stable and stay in close association in the membrane and represent the active form of PS, whereas full-length PS is rapidly degraded. In the current model of c-secretase activity, both the aminoterminal and carboxy-terminal fragments of PS are required for the actual aspartyl protease activity, whereas Nct and Aph-1 are attributed a substrate recognition function. Fully active c-secretase matures in discrete steps: first Nct and Aph-1 form a complex, then PS binds to this complex, and finally Pen2 will complete the complex and may facilitate auto-cleavage of PS. (Li et al. 2009 ). More proteins interact with c-secretase and may modulate its function (Winkler et al. 2009 ). More than 50 c-secretase substrates have been discovered (Beel and Sanders 2008; Wakabayashi and de Strooper 2008) , including APP, Notch, the neuregulin binding partner ErbB4, N-cadherin, p75NTR, and others. In a study using different knockouts of c-secretase components heterozygous deletion of PS1, Aph-1a or Nct resulted in a reduction of c-secretase activity ranging from 25% (PS1 ?/-) to 64% for PS1 ?/-; Nct ?/-mice (Li et al. 2009 ). In this study, a c-secretase reduction of 30% or lower (PS1 ?/-or Aph-1a ?/-mice) was not associated with an increased rate of squamous cell carcinomas (that is caused by deficient Notch signaling), while Nct ?/-and PS1 ?/-; Nct ?/-mice with 50 and 64% reductions in c-secretase activity, respectively, did have increased carcinogenesis. Interestingly, a moderate reduction of c-secretase activity by 30% through Aph-1a heterozygous knockout was enough to reduce amyloid pathology in APPswe/PS1DE9 mice. A series of studies used a conditional knockout approach of c-secretase proteins using the Cre recombinase system under a promoter that is expressed only in the postnatal forebrain (Yu et al. 2001; Saura et al. 2005; Tabuchi et al. 2009 ). From these studies, it can be concluded that a complete inactivation of c-secretase through conditional knockout of Nct (Tabuchi et al. 2009 ) in a normally developed brain leads to progressive neurodegeneration. Conditional knockout of PS1 does not lead to a progressive neurodegenerative phenotype, possibly because the loss of PS1 can be partially compensated for by PS2. Nevertheless, these mice exhibited some cognitive deficits in behavior testing (Yu et al. 2001) . Importantly, these deficits were unlikely to reflect a deficit in Notch signaling, as expression of Notch target genes was unaffected. When the conditional PS1 knockout mice were crossed with APP transgenic mice, Ab production was clearly reduced, but the beneficial effect on memory and learning in behavior tests was statistically significant only in young (3 months) mice, while in older mice (15-17 months) the effect was reduced and not statistically significant (Saura et al. 2005) . Another recent report indicates that genetic ablation of Aph-1b and c in mice reduces c-secretase-mediated APP cleavage (specifically the generation of the more amyloidogenic Ab1-42), but does not affect Notch cleavage (Serneels et al. 2009 ). Genetic ablation of Aph-1b/c resulted in subtle behavioral abnormalities that were reminiscent of those seen in BACE1 -/-mice (Laird et al. 2005 , Savonenko et al. 2008 ) and may reflect a deficit in processing of neuregulin (which is also a BACE1 substrate) or its binding partner ErbB4. However, Aph-1b/c knockout resulted in a complete reversal of cognitive deficits in APP/PS1 transgenic mice, together with a reduction in amyloid pathology. The oldest mice used in this study were 11 months old, and at the moment, no data are published on whether the beneficial effects of Aph-1b/c knockout can be sustained in older APP/PS1 transgenic animals.
The orphan G-protein coupled receptor 3 (Gpr3) was recently shown to affect c-secretase assembly and subcellular location (Thathiah et al. 2009 ). Gpr3, although not an essential part of the c-secretase complex, facilitated the assembly of the four required proteins to the fully active protein complex and targeted c-secretase preferentially to lipid rafts and the plasma membrane leading to increased Ab 1-40 and 1-42 production in vitro and in vivo, whereas genetic ablation of Gpr3 led to a reduction of Ab production in young mice. Notch signaling was not affected by Gpr3 knockout. The effects of Gpr3 expression on cognition and behavior have not been reported yet.
Taken together, good evidence has now been provided that c-secretase activity exists as separate subspecies with different subunit composition and, thus, different structures, substrate specificities, and binding partners. This provides a good rationale for the development of c-secretase inhibitors with relative specificity for APP over Notch, and compounds with such a profile have been described already Cole et al. 2009 ). However, results from the conditional knockout studies suggest that reduced c-secretase activity is associated with detrimental side effects in the brain especially in older animals. It remains to be seen whether these effects reflect a deficit in APP cleavage and processing or are a due to reduced cleavage of other substrates (e.g., neuregulin or ErbB4) and how the human brain is affected by c-secretase inhibition.
PS1 also has a role in endoplasmic reticulum-mediated calcium release. At the moment, there is still some controversy about the exact mechanism, as PS1 may act as a calcium leak channel or it may enhance the opening of the inositol-3-phosphate receptor (IP3R); however, it does seem clear that PS1 causes an increase in cytosolic calcium concentrations (Tu et al. 2006 , Nelson et al. 2007 , Cheung et al. 2008 . Interestingly, although this function has been reported to be independent of c-secretase activity, it is also affected by AD-associated PS1 mutations which cause higher cytosolic calcium concentrations when cells are stimulated (Guo et al. 1997; Chan et al. 2000) . While csecretase activity is not required for PS1-mediated gating of (IP3Rs), IP3Rs gating through PS1 is important for c-secretase function (Cheung et al. 2008) . These data provide a further link between disturbed calcium homeostasis and AD, where increased cytosolic calcium concentrations may be associated with increased sensitivity to excitotoxicity, epileptiform discharges and seizures as well as skewed information processing, as relatively smaller amounts of synaptic input are required to elicit an action potential or calcium dependent signals, e.g., through calcium/calmodulin dependent kinases.
Full-Length APP
The search for a physiologic role of full-length APP is inseparably linked to the functions of APP cleavage products. Overexpression of human APP (either wt or with the Swedish mutation) in mice is associated with increased size of cortical neurons, whereas overexpression of PS1 is not (Oh et al. 2009 ). At the moment, it is not clear whether this is an effect of full-length APP or one of its cleavage products. Interestingly, increased size of neuron somata, nuclei and nucleoli in the hippocampus and cortex has also been observed in postmortem brains of humans that show AD-like pathology but had no cognitive deficits (Riudavets et al. 2007 , Iacono et al. 2008 , Iacono et al. 2009 ).
APP deficient mice show a number of phenotypes, including reduced body and brain seize, impaired learning and LTP, reduced grip strength, hypersensitivity to seizures, and increased frequency of corpus callosum dysgenesis (Ring et al. 2007 ). These phenotypes mostly become apparent during early postnatal development, rather than in adult stages. By reintroducing only the sAPPa fragment into APP deficient mice, it was demonstrated that lack of sAPPa is responsible for most of the phenotypes observed in APP mice (Ring et al. 2007 ). While single genetic ablation of APP or APP-like protein (APLP) 1 and 2 results in viable mice, deletion of APP and APLP2, APLP1 and APLP2, or APP and APLPs 1 and 2 results in perinatal lethality suggesting redundancy in some of the physiologic functions of these proteins. Therefore, it seems that there is an important role for APP in brain development that is in large part mediated by sAPPa and partly overlaps with functions of APLPs 1 and 2. Transient axonal glycoprotein l (TAG1) was recently discovered to act as a binding partner for full-length APP (Ma et al. 2008 ). TAG1 binding to APP induced APP processing (preferentially through a-and c-secretase), and through genetic manipulations it was shown that the AICD-mediated signaling through Fe65 inhibited neuronal differentiation of embryonic stem cells and kept the stem cells in a mode of self-renewal.
Conclusion
Great progress has been made in characterizing the molecules involved in APP processing and the functions of APP cleavage products. As a result, a complex picture has emerged for the physiologic and pathologic roles of APP. A clearly defined role for sAPPb in axon pruning has been demonstrated, and good evidence exists for sAPPa having important roles in brain development and synaptic plasticity, as well as growth factor-like properties. Whether AICD acts as a transcriptional activator remains controversial. Recent data indicate that it may play a role in embryonic neural stem cell development, but also regulate APP trafficking and, thus, modulate APP processing. Neuronal activity modulates APP processing pathways, suggesting important roles for activity-induced APP cleavage products in regulating neuronal excitability and synaptic plasticity. The finding that cathepsin B can act as a b-secretase for wtAPP, but not mtAPP, may have great impact on AD research and, therefore, merits further investigation and corroboration. Ab remains the main suspect in AD pathogenesis, and the molecular mechanisms and binding partners of soluble Ab toxicity are beginning to be unraveled. Posttranslational modifications of Ab may contribute to Ab oligomerization and toxicity, as may the extent to which Ab is cleared by Ab-degrading proteases. With regard to APP processing enzymes, it has become very clear that all involved enzymes have multiple substrates and are not specific for APP, and that PS1 has functions beyond c-secretase. While initially concerns were great that c-secretase inhibitors inevitably would impair Notch processing, a better understanding of c-secretase mechanics has helped to make the development of Notch sparing c-secretase inhibitors seem a very feasible task. However, while Notch appears to become less of a problem to drug development, the sheer quantity of substrates for both b-and c-secretase is a reason for concern. Combining moderate b-and c-secretase inhibition may be a tangible strategy to reduce potential side effects of secretase inhibition while additively reducing Ab production. However, since c-secretase requires a substrate to be cleaved first by a sheddase, b-and c-secretase may, in fact, share multiple substrates, neuregulin/ErbB4 and the voltage-gated sodium channel b2-subunit being good examples. A detailed understanding of the molecular aspects of secretase activity may help to generate secretase inhibitors with high specificity for APP. Also, it is important to understand the physiologic functions of secretases in the aged human brain to judge the potential for mechanism-based side effects of secretase inhibitors. The major challenge of course remains treating AD patients, who at the time of diagnosis are in an advanced disease stage when compared to AD mouse models. Therefore, improved diagnosis criteria and tools seem indispensable requirements for better efficacy of any anti-amyloid strategy. Considering all challenges that have to be met by anti-amyloid or secretase-focused therapies, the development of non-amyloid-based therapeutic strategies would be a very welcome addition to the portfolio of AD research.
